BioLineRx (BLRX) EPS (Basic): 2023-2025
Historic EPS (Basic) for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to -$0.00.
- BioLineRx's EPS (Basic) rose 73.25% to -$0.00 in Q2 2025 from the same period last year, while for Jun 2025 it was -$0.00, marking a year-over-year increase of 89.81%. This contributed to the annual value of -$0.01 for FY2024, which is 81.60% up from last year.
- Per BioLineRx's latest filing, its EPS (Basic) stood at -$0.00 for Q2 2025, which was down 2.84% from -$0.00 recorded in Q1 2025.
- In the past 5 years, BioLineRx's EPS (Basic) registered a high of $0.02 during Q2 2023, and its lowest value of -$0.02 during Q4 2023.
- Its 3-year average for EPS (Basic) is -$0.00, with a median of -$0.00 in 2024.
- The largest annual percentage gain for BioLineRx's EPS (Basic) in the last 5 years was 100.21% (2024), contrasted with its biggest fall of 116.97% (2024).
- Quarterly analysis of 3 years shows BioLineRx's EPS (Basic) stood at -$0.02 in 2023, then soared by 100.21% to $0.00 in 2024, then surged by 73.25% to -$0.00 in 2025.
- Its EPS (Basic) was -$0.00 in Q2 2025, compared to -$0.00 in Q1 2025 and $0.00 in Q4 2024.